Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Qualit...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, Van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John, Weisel, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078427/
https://www.ncbi.nlm.nih.gov/pubmed/33326255
http://dx.doi.org/10.1200/JCO.20.01370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078427/
https://www.ncbi.nlm.nih.gov/pubmed/33326255
http://dx.doi.org/10.1200/JCO.20.01370

Ejemplares similares